A dermocosmetic regimen is able to mitigate skin sensitivity induced by a retinoid-based fixed combination treatment for acne: Results of a randomized clinical trial.
acne
cleanser
cream
dermocosmetic regimen
retinoid-induced skin discomfort
skin sensitivity
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
15 Dec 2023
15 Dec 2023
Historique:
revised:
18
10
2023
received:
31
05
2023
accepted:
04
12
2023
medline:
16
12
2023
pubmed:
16
12
2023
entrez:
16
12
2023
Statut:
aheadofprint
Résumé
Topical retinoids cause retinoid-induced skin discomfort (RISD) mainly during the first weeks of use leading to noncompliance and premature treatment discontinuation. A dermocosmetic (DC) may help to reduce treatment-related signs and symptoms and improve adherence. To assess the benefit of a DC regimen compared to a routine skin care regimen (RC) by reducing RISD signs and symptoms induced by a retinoid/benzoyl peroxide fixed-drug combination in subjects with acne. Double-blind, randomized, comparative study in subjects ≥16 years with mild to moderate acne candidates to a topical adapalene/BPO fixed drug combination (A/BPO). Evaluations took place at Day 0, 7, 14, 28, and 84 and included erythema, desquamation, burning, itching and stinging and RISD (SD, a composite score of local treatment-related signs and symptoms and acne severity. Subjects used daily the DC or RC together with the fixed combination for 84 days. Eighty-eight subjects were included, the mean age was 21 years; 84% were females. At Day 0 the SD score was 0.8 in both groups. A statistically significant difference in terms of skin sensitivity with DC compared to RC (1.6 points, vs. 2.4 points p < 0.05) was observed at Day 14. Clinical sign and symptom scores were more reduced with DC than with RC at all time points. Acne severity improved in both groups. DC significantly reduces A/BPO-related RISD compared to RC, especially during the first 14 days of treatment, without interfering with the clinical efficacy of the treatment, thus helping to maintain treatment adherence.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
Platsidaki E, Dessinioti C. Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne. F1000Res. 2018;7:7.
Dreno B. What is new in the pathophysiology of acne, an overview. J Eur Acad Dermatol Venereol. 2017;31(Suppl 5):8-12.
Bagatin E, Freitas THP, Rivitti-Machado MC, et al. Adult female acne: a guide to clinical practice. Ann Bras Dermatol. 2019;94(1):62-75.
Addor FA, Schalka S. Acne in adult women: epidemiological, diagnostic and therapeutic aspects. Ann Bras Dermatol. 2010;85(6):789-795.
Dreno B, Martin R, Moyal D, Henley JB, Khammari A, Seité S. Skin microbiome and acne vulgaris: staphylococcus, a new actor in acne. Exp Dermatol. 2017;26(9):798-803.
Degitz K, Placzek M, Borelli C, Plewig G. Pathophysiology of acne. J Dtsch Dermatol Ges. 2007;5(4):316-323.
Kurokawa I, Layton AM, Ogawa R. Updated treatment for acne: targeted therapy based on pathogenesis. Dermatol Ther. 2021;11(4):1129-1139.
Leyden J, Stein-Gold L, Weiss J. Why topical Retinoids are mainstay of therapy for acne. Dermatol Ther. 2017;7(3):293-304.
Phillips TJ. An update on the safety and efficacy of topical retinoids. Cutis. 2005;75(2 Suppl):14-22.
Tirado-Sánchez A, Espíndola YS, Ponce-Olivera RM, Bonifaz A. Efficacy and safety of adapalene gel 0.1% and 0.3% and tretinoin gel 0.05% for acne vulgaris: results of a single-center, randomized, double-blinded, placebo-controlled clinical trial on Mexican patients (skin type III-IV). J Cosm Dermatol. 2013;12(2):103-107.
Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J Drugs Dermatol. 2008;7(6 Suppl):s3-s10.
Tan J, Bissonnette R, Gratton D, Kerrouche N, Canosa JM. The safety and efficacy of four different fixed combination regimens of adapalene 0.1%/benzoyl peroxide 2.5% gel for the treatment of acne vulgaris: results from a randomised controlled study. Eur J Dermatol. 2018;28(4):502-508.
Hayashi N, Kawashima M. Study of the usefulness of moisturizers on adherence of acne patients treated with adapalene. J Dermatol. 2014;41(7):592-597.
Draelos ZD, Matsubara A, Smiles K. The effect of 2% niacinamide on facial sebum production. J Cosmet Laser Ther. 2006;8(2):96-101.
Meunier M, Chapuis E, Lapierre L, et al. Mannose-6-phosphate complex and improvement in biomechanical properties of the skin. J Cosm Dermatol. 2021;20(6):1598-1610.
Camargo FB Jr, Gaspar LR, Maia Campos PM. Skin moisturizing effects of panthenol-based formulations. J Cosmet Sci. 2011;62(4):361-370.
Dreno B, Poli F, Pawin H, et al. Development and evaluation of a global acne severity scale (GEA scale) suitable for France and Europe. J Eur Acad Dermatol Venereol. 2011;25(1):43-48.
Culp L, Moradi Tuchayi S, Alinia H, Feldman SR. Tolerability of topical Retinoids: are there clinically meaningful differences among topical Retinoids? J Cutan Med Surg. 2015;19(6):530-538.
Yang Z, Zhang Y, Lazic Mosler E, et al. Topical benzoyl peroxide for acne. Cochrane Database Syst Rev. 2020;3(3): Cd011154.
Dreno B, Thiboutot D, Gollnick H, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010;49(4):448-456.
Nast A, Dreno B, Bettoli V, et al. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol. 2016;30(8):1261-1268.
Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.
Blaak J, Staib P. The relation of pH and skin cleansing. Curr Probl Dermatol. 2018;54:132-142.
Dreno B, Bettoli V, Araviiskaia E, Sanchez Viera M, Bouloc A. The influence of exposome on acne. J Eur Acad Dermatol Venereol. 2018 May;32(5):812-819.
Araviiskaia E, Lopez Estebaranz JL, Pincelli C. Dermocosmetics: beneficial adjuncts in the treatment of acne vulgaris. J Dermatol Treat. 2021;32(1):3-10.
Araviiskaia E, Dréno B. The role of topical dermocosmetics in acne vulgaris. J Eur Acad Dermatol Venereol. 2016;30(6):926-935.